Evidence map›Paper›PMID 34503354›Full record

ArticleThe Journal of urology2021

Reply by Authors.

Lauren Folgosa Cooley, Adaeze A Emeka, Travis J Meyers, Phillip R Cooper, Daniel W Lin, Antonio Finelli, James A Eastham, Christopher J Logothetis, Leonard S Marks, Danny Vesprini and 12 more

Abstract readComment
PubMed Publisher
In one paragraph

Article in The Journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Lauren Folgosa CooleyDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Adaeze A EmekaDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Travis J MeyersDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
Phillip R CooperDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Daniel W LinFred Hutchinson Cancer Research Center, Cancer Prevention Program, Public Health Sciences, Seattle, Washington.
Antonio FinelliDivision of Urology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
James A EasthamUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Christopher J LogothetisDepartments of Genitourinary Medical Oncology and Urology, the University of Texas M. D. Anderson Cancer Center, Houston, Texas.
Leonard S MarksDepartment of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Danny VespriniOdette Cancer Centre, Sunnybrook Health and Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
S Larry GoldenbergDepartment of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Celestia S HiganoDepartment of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Christian P PavlovichThe Brady Urological Institute, the Johns Hopkins University School of Medicine, Baltimore, Maryland.
June M ChanDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
Todd M MorganDepartment of Urology, University of Michigan, Ann Arbor, Michigan.
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, Ohio.
Daniel A BarocasDepartment of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Stacy LoebDepartments of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs Medical Center, New York, New York.
Brian T HelfandDivision of Urology, NorthShore University Health System, Evanston, Illinois.
Denise M ScholtensDivision of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
John S WitteDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
William J CatalonaDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Funding

Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A., HUSSAIN, MAHA H · 2015 to 2025
$19.9M
NCI NIH HHS P50 CA180995
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34503354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.